chlorine has been researched along with Cough in 17 studies
chloride : A halide anion formed when chlorine picks up an electron to form an an anion.
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Excerpt | Relevance | Reference |
---|---|---|
"The effect of a single, high dose of aspirin has been assessed against low chloride cough challenge." | 9.07 | The low-chloride cough response is not inhibited by a single, high dose of aspirin. ( Barnes, PJ; Fuller, RW; Stone, RA, 1992) |
"The pH and chloride levels in exhaled breath condensate and capsaicin cough threshold (C5) were measured in 50 patients with chronic cough and in 16 healthy controls." | 5.11 | Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. ( Chung, KF; Mann, B; Nguyen, LT; Niimi, A; Usmani, O, 2004) |
"The effect of a single, high dose of aspirin has been assessed against low chloride cough challenge." | 5.07 | The low-chloride cough response is not inhibited by a single, high dose of aspirin. ( Barnes, PJ; Fuller, RW; Stone, RA, 1992) |
" Using amiloride, a sodium ion blocker, and bumetanide, a blocker of the chloride ion co-transport system, the importance oftransepithelial sodium and chloride ion transport for support of the cough reflex was determined." | 3.75 | Ionic support of the cough reflex. ( Banach, B; Mikołajek-Bedner, W; Sroczyński, T; Słuczanowska-Glabowska, S, 2009) |
" Common adverse events in part B included cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%])." | 2.82 | Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. ( Cooke, J; Cunningham, S; Davies, JC; Green, Y; Harris, WT; Lapey, A; Regelmann, WE; Robertson, S; Rosenfeld, M; Sawicki, GS; Southern, KW, 2016) |
"Cough was then induced at 0." | 2.67 | Effect of frusemide on cough responses to chloride-deficient solution in normal and mild asthmatic subjects. ( Barnes, PJ; Chung, KF; Stone, RA, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (29.41) | 18.7374 |
1990's | 5 (29.41) | 18.2507 |
2000's | 5 (29.41) | 29.6817 |
2010's | 1 (5.88) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
Authors | Studies |
---|---|
Yi, W | 1 |
Long, X | 1 |
Liu, J | 1 |
Shi, L | 1 |
Chen, Z | 1 |
Yang, J | 1 |
Yang, Z | 1 |
Lv, Z | 1 |
Fan, H | 1 |
Davies, JC | 1 |
Cunningham, S | 1 |
Harris, WT | 1 |
Lapey, A | 1 |
Regelmann, WE | 1 |
Sawicki, GS | 1 |
Southern, KW | 1 |
Robertson, S | 1 |
Green, Y | 1 |
Cooke, J | 1 |
Rosenfeld, M | 1 |
Banach, B | 2 |
Mikołajek-Bedner, W | 1 |
Sroczyński, T | 1 |
Słuczanowska-Glabowska, S | 1 |
Numasawa, T | 1 |
Shiba, K | 1 |
Nakazawa, K | 1 |
Umezaki, T | 1 |
Niimi, A | 1 |
Nguyen, LT | 1 |
Usmani, O | 1 |
Mann, B | 1 |
Chung, KF | 2 |
Lukela, M | 1 |
DeGuzman, D | 1 |
Weinberger, S | 1 |
Saint, S | 1 |
Mazzone, SB | 1 |
McGovern, AE | 1 |
Stone, RA | 2 |
Barnes, PJ | 3 |
Cavigioli, G | 1 |
Pelucchi, A | 1 |
Mastropasqua, B | 1 |
Chiesa, M | 1 |
Marazzini, L | 1 |
Foresi, A | 1 |
Tyrakowski, T | 1 |
Wojciechowska, I | 1 |
Mościbroda, A | 1 |
Greczko, I | 1 |
Nyitray, L | 1 |
Fuller, RW | 2 |
Stone, R | 1 |
Godden, DJ | 1 |
Borland, C | 1 |
Lowry, R | 1 |
Higenbottam, TW | 1 |
Higenbottam, T | 1 |
McCombs, ML | 1 |
Gecse, A | 1 |
Zsilinszky, E | 1 |
Lonovics, J | 1 |
West, GB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation[NCT01705145] | Phase 3 | 35 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux[NCT00451841] | 30 participants (Anticipated) | Observational | 2007-03-31 | Terminated (stopped due to IRB approval not renewed/approval lapsed. Prior status: insufficient enrollment; study suspended pending analysis) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
BMI = (Weight [in kg]) divided by (Stature [in meters])^2. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Baseline, Week 24
Intervention | kilogram per square meter (kg/m^2) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 0.332 |
Part B: Ivacaftor 75 mg | 0.314 |
Part B: Overall Ivacaftor | 0.319 |
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | centimeters (cm) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 2.5 |
Part B: Ivacaftor 75 mg | 3.5 |
Part B: Overall Ivacaftor | 3.3 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | millimole per liter (mmol/L) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | -47.07 |
Part B: Ivacaftor 75 mg | -46.78 |
Part B: Overall Ivacaftor | -46.86 |
Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | kilograms (kg) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 1.00 |
Part B: Ivacaftor 75 mg | 1.50 |
Part B: Overall Ivacaftor | 1.36 |
"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants." (NCT01705145)
Timeframe: Part A: Up to 93 Days
Intervention | participants (Number) | ||
---|---|---|---|
AEs | SAEs | Related AEs | |
Part A: Ivacaftor 50 mg | 3 | 0 | 1 |
Part A: Ivacaftor 75 mg | 5 | 0 | 3 |
Part A: Overall Ivacaftor | 8 | 0 | 4 |
Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor [M1] and ivacaftor carboxylate [M6]) up to 24 hours post-dose on Day 4 (Hour 0 [pre-dose] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part A: up to 24 hours post-dose on Day 4
Intervention | nanogram per milliliter (ng/mL) (Mean) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ivacaftor: Hour 0 on Day 1 | Ivacaftor: Hour 0 on Day 4 | Ivacaftor: 2 Hours Post-Dose on Day 4 | Ivacaftor: 3 Hours Post-Dose on Day 4 | Ivacaftor: 6 Hours Post-Dose on Day 4 | Ivacaftor: 24 Hours Post-Dose on Day 4 | M1: Hour 0 on Day 1 | M1: Hour 0 on Day 4 | M1: 2 Hours Post-Dose on Day 4 | M1: 3 Hours Post-Dose on Day 4 | M1: 6 Hours Post-Dose on Day 4 | M1: 24 Hours Post-Dose on Day 4 | M6: Hour 0 on Day 1 | M6: Hour 0 on Day 4 | M6: 2 Hours Post-Dose on Day 4 | M6: 3 Hours Post-Dose on Day 4 | M6: 6 Hours Post-Dose on Day 4 | M6: 24 Hours Post-Dose on Day 4 | |
Part A: Overall Ivacaftor | 0.00 | 396 | 726 | 957 | 542 | 124 | 0.00 | 1240 | 1540 | 2310 | 1580 | 389 | 0.00 | 1150 | 1050 | 1300 | 1390 | 439 |
"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received." (NCT01705145)
Timeframe: Part B: Up to 28 Weeks
Intervention | participants (Number) | ||
---|---|---|---|
AEs | SAEs | Related AEs | |
Part B: Ivacaftor 50 mg | 10 | 3 | 3 |
Part B: Ivacaftor 75 mg | 23 | 3 | 8 |
Part B: Overall Ivacaftor | 33 | 6 | 11 |
Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 [predose] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part B: up to 24 hours post-dose on Day 168
Intervention | ng/mL (Mean) | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ivacaftor: Hour 0 on Day 1 | Ivacaftor: Hour 0 on Day 14 | Ivacaftor: 2 Hours Post-Dose on Day 14 | Ivacaftor: 3 Hours Post-Dose on Day 14 | Ivacaftor: 6 Hours Post-Dose on Day 14 | Ivacaftor: Hour 0 on Day 56 | Ivacaftor: 1 Hour Post-Dose on Day 56 | Ivacaftor: Hour 0 on Day 112 | Ivacaftor: 4 Hours Post-Dose on Day 112 | Ivacaftor: 6 Hours Post-Dose on Day 112 | Ivacaftor: Hour 0 on Day 168 | Ivacaftor: 24 Hours Post-Dose on Day 168 | M1: Hour 0 on Day 1 | M1: Hour 0 on Day 14 | M1: 2 Hours Post-Dose on Day 14 | M1: 3 Hours Post-Dose on Day 14 | M1: 6 Hours Post-Dose on Day 14 | M1: Hour 0 on Day 56 | M1: 1 Hour Post-Dose on Day 56 | M1: Hour 0 on Day 112 | M1: 4 Hours Post-Dose on Day 112 | M1: 6 Hours Post-Dose on Day 112 | M1: Hour 0 on Day 168 | M1: 24 Hours Post-Dose on Day 168 | M6: Hour 0 on Day 1 | M6: Hour 0 on Day 14 | M6: 2 Hours Post-Dose on Day 14 | M6: 3 Hours Post-Dose on Day 14 | M6: 6 Hours Post-Dose on Day 14 | M6: Hour 0 on Day 56 | M6: 1 Hour Post-Dose on Day 56 | M6: Hour 0 on Day 112 | M6: 4 Hours Post-Dose on Day 112 | M6: 6 Hours Post-Dose on Day 112 | M6: Hour 0 on Day 168 | M6: 24 Hours Post-Dose on Day 168 | |
Part B: Overall Ivacaftor | 0.00 | 614 | 932 | 1080 | 1140 | 448 | 514 | 596 | 1080 | 1010 | 500 | 207 | 0.00 | 1580 | 1870 | 2280 | 2670 | 1340 | 1170 | 1680 | 2450 | 2500 | 1460 | 602 | 0.00 | 1520 | 1430 | 1630 | 2090 | 1510 | 1310 | 1660 | 1810 | 2130 | 1520 | 632 |
1 review available for chlorine and Cough
Article | Year |
---|---|
Research in cystic fibrosis: a review.
Topics: Biological Transport; Calcium; Cells, Cultured; Child; Chlorides; Cough; Cystic Fibrosis; Digestive | 1973 |
6 trials available for chlorine and Cough
Article | Year |
---|---|
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Topics: Aminophenols; Child, Preschool; Chloride Channel Agonists; Chlorides; Cough; Cystic Fibrosis; Cystic | 2016 |
Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough.
Topics: Adult; Asthma; Breath Tests; Bronchiectasis; Capsaicin; Chlorides; Chronic Disease; Cough; Female; G | 2004 |
Effect of frusemide on cough responses to chloride-deficient solution in normal and mild asthmatic subjects.
Topics: Adult; Asthma; Bronchial Provocation Tests; Chlorides; Cough; Double-Blind Method; Female; Forced Ex | 1993 |
The low-chloride cough response is not inhibited by a single, high dose of aspirin.
Topics: Aspirin; Bicarbonates; Chlorides; Cough; Double-Blind Method; Humans; Sodium; Sodium Bicarbonate | 1992 |
Contrasting effects of prostaglandins E2 and F2 alpha on sensitivity of the human cough reflex.
Topics: Adolescent; Adult; Capsaicin; Chlorides; Citrates; Citric Acid; Cough; Dinoprost; Dinoprostone; Doub | 1992 |
Chemical specificity of coughing in man.
Topics: Acetates; Acetic Acid; Administration, Intranasal; Adolescent; Adult; Aerosols; Bicarbonates; Chlori | 1986 |
10 other studies available for chlorine and Cough
Article | Year |
---|---|
Risk factors for recurrent positive results of the nucleic acid amplification test for COVID-19 patients: a retrospective study.
Topics: Adult; Aged; Chlorides; Cough; COVID-19; COVID-19 Nucleic Acid Testing; False Positive Reactions; Fe | 2021 |
Ionic support of the cough reflex.
Topics: Amiloride; Animals; Bumetanide; Chlorides; Cough; Female; In Vitro Techniques; Ion Transport; Male; | 2009 |
Membrane potential changes in vocal cord tensor motoneurons during breathing, vocalization, coughing and swallowing in decerebrate cats.
Topics: Analysis of Variance; Animals; Cats; Chlorides; Cough; Decerebrate State; Deglutition; Female; Male; | 2004 |
Clinical problem-solving. Unfashionably late.
Topics: Adolescent; Biopsy; Burkholderia cepacia; Burkholderia Infections; Chest Pain; Chlorides; Cough; Cys | 2005 |
Na+-K+-2Cl- cotransporters and Cl- channels regulate citric acid cough in guinea pigs.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Chloride Channels; Chlorides; Citric Acid | 2006 |
Prevalence and repeatability of the cough response induced by inhalation of low chloride ion solutions in normal subjects.
Topics: Administration, Inhalation; Adolescent; Adult; Chlorides; Cough; Female; Forced Expiratory Volume; H | 1995 |
[Electrophysiologic studies of local ion transport changes in the tracheal wall in vitro].
Topics: Amiloride; Animals; Bumetanide; Chi-Square Distribution; Chlorides; Cough; Epithelium; Gagging; In V | 1997 |
[Analysis of antitussive syrup for the use of diabetics].
Topics: Antitussive Agents; Chlorides; Codeine; Cough; Diabetes Mellitus; Drug Stability; Humans; Sorbitol | 1977 |
The ionic composition of airway surface liquid and coughing.
Topics: Aerosols; Bronchi; Chemoreceptor Cells; Chlorides; Cough; Epithelium; Glucose; Humans; Hydrogen-Ion | 1987 |
C-phenylglycine-n-heptyl ester as an inhibitor of mediators of allergic reactions.
Topics: Acetylcholine; Aerosols; Anaphylaxis; Animals; Antigens; Barium; Bradykinin; Chlorides; Cough; Drug | 1971 |